Literature DB >> 1833227

Cell motility, a principal requirement for metastasis.

M L Stracke1, S A Aznavoorian, M E Beckner, L A Liotta, E Schiffmann.   

Abstract

In studying the role of motility in the metastasis of tumor cells, we have described an autocrine motility factor. This agent, which stimulates random motility, probably contributes to the initial dissociation of the cells from the primary tumor mass. Extracellular matrix components, via several different mechanisms, may facilitate the crossing of biological barriers by the cells prior to the entry into the circulation. In locating at new sites, the tumor cells may be induced to exit from the circulation in response to attractants such as IGFs that could emanate from the target organ. These same growth factors could then stimulate cellular proliferation for another metastatic cycle. It is quite probable that detection of AMF may provide a new tool in cancer diagnosis. The complete characterization of AMF may also yield valuable therapeutic approaches: design of low molecular size antagonists of the attractants and antibodies that might be effective therapeutically as well as diagnostically. It seems clear, in any event, that immobilizing the tumor cell may be a crucial step in inhibiting metastasis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1833227     DOI: 10.1007/978-3-0348-7494-6_10

Source DB:  PubMed          Journal:  EXS        ISSN: 1023-294X


  10 in total

1.  The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration.

Authors:  Xingding Zhang; Yu Jing; Yang Qin; Sally Hunsucker; Huimin Meng; Jun Sui; Yelin Jiang; Li Gao; Gangli An; Nan Yang; Robert Z Orlowski; Lin Yang
Journal:  Int J Biochem Cell Biol       Date:  2012-04-16       Impact factor: 5.085

2.  Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well.

Authors:  S Koop; E E Schmidt; I C MacDonald; V L Morris; R Khokha; M Grattan; J Leone; A F Chambers; A C Groom
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

3.  Laminin 332 expression in breast carcinoma.

Authors:  Soon-Young Kwon; Seoung W Chae; Sharon P Wilczynski; Ahmad Arain
Journal:  Appl Immunohistochem Mol Morphol       Date:  2012-03

4.  Laminin 332 expression and prognosis in breast cancer.

Authors:  Philip M Carpenter; Argyrios Ziogas; Emma M Markham; Alegria S Cantillep; Rui Yan; Hoda Anton-Culver
Journal:  Hum Pathol       Date:  2018-08-17       Impact factor: 3.466

5.  Differential purification of autocrine motility factor derived from a murine protein-free fibrosarcoma.

Authors:  H Watanabe; K Kanbe; M Chigira
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

6.  Detection of candidates for cancer cell motility inhibitory protein in the Dunning adenocarcinoma model.

Authors:  J L Mohler; W E Bakewell; Y Sharief; W B Coleman; C H Chay; S M Silvers; G J Smith
Journal:  Clin Exp Metastasis       Date:  1995-11       Impact factor: 5.150

Review 7.  The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.

Authors:  Amaury G Dumont; Sarah N Dumont; Jonathan C Trent
Journal:  Chin J Cancer       Date:  2012-05-24

8.  A function for filamentous alpha-smooth muscle actin: retardation of motility in fibroblasts.

Authors:  L Rønnov-Jessen; O W Petersen
Journal:  J Cell Biol       Date:  1996-07       Impact factor: 10.539

9.  Migration of breast cancer cell lines in response to pulmonary laminin 332.

Authors:  Philip M Carpenter; Priyanka Sivadas; Spencer S Hua; Cally Xiao; Alyssa B Gutierrez; Tuan Ngo; Paul D Gershon
Journal:  Cancer Med       Date:  2016-11-22       Impact factor: 4.452

10.  Solute-dependent activation of cell motility in strongly hypertonic solutions in Dictyostelium discoideum, human melanoma HTB-140 cells and walker 256 carcinosarcoma cells.

Authors:  Włodzimierz Korohoda; Magdalena Kucia; Ewa Wybieralska; Magdalena Wianecka-Skoczeń; Agnieszka Waligórska; Justyna Drukała; Zbigniew Madeja
Journal:  Cell Mol Biol Lett       Date:  2011-05-25       Impact factor: 5.787

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.